Search

Showing total 4,504 results

Search Constraints

Start Over You searched for: Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years Journal alimentary pharmacology & therapeutics Remove constraint Journal: alimentary pharmacology & therapeutics Publisher wiley-blackwell Remove constraint Publisher: wiley-blackwell
4,504 results

Search Results

151. Editorial: MAFLD and outcome prediction.

159. Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply.

162. Letter: systematic review with meta‐analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B—authors' reply.

163. Letter: association of laboratory indexes and magnetic resonance elastography‐associated liver stiffness with complications and mortality.

165. Letter: severe COVID‐19 infection and biologic therapies—a cohort study of 7 808 patients in France.

169. Letter: disentangling the role of redox‐active compounds in the development of inflammatory bowel diseases – moving towards causal associations.

170. Letter: disentangling the role of redox‐active compounds in the development of inflammatory bowel diseases—moving towards causal associations. Authors' reply.

173. Editorial: clinical outcomes in lean NAFLD—the devil is in the details.

175. Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation.

181. Letter: dietitians are more than coaches.

183. Letter: be careful of gastrointestinal CMV infection in adverse event from ICIs therapy in solid tumours—Authors' reply.

190. Editorial: definition of factors associated with poor quality of life in patients with IBS—but where to from here? Authorsʼ reply.

192. Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients—authors' reply.

196. Editorial: real‐world evidence of tofacitinib and vedolizumab in ulcerative colitis—are we one step closer to better positioning therapies after anti‐TNF failure?

197. Editorial: let's get physical—long‐term benefits of vigorous physical activity in patients with nonalcoholic fatty liver disease. Authors' reply.

200. Letter: improved alanine aminotransferase level in non‐cirrhotic and low‐viral load chronic hepatitis B patients treated with nucleotide/nucleoside analogues —authorsʼ reply.